Gyroscope Therapeutics Ltd, a gene therapy company founded by Syncona Ltd, has received $148 million in a Series C financing round to advance its lead product for geographic atrophy secondary to age-related macular degeneration (AMD), a leading cause of blindness. The financing was led by Forbion Capital Partners with a significant contribution from Syncona, which now owns 54% of the company.
